Developmental and epileptic encephalopathies (DEE) are characterized by the co-occurrence of epilepsy and intellectual disability (ID), typically with developmental plateauing or regression associated with frequent epileptiform activity. The cause of DEE remains unknown in the majority of cases. We performed whole-genome sequencing (WGS) in 197 individuals with unexplained DEE and pharmaco-resistant seizures and in their unaffected parents. We focused our attention on de novo mutations (DNMs) and identified candidate genes containing such variants. We sought to identify additional subjects with DNMs in these genes by performing targeted sequencing in another series of individuals with DEE and by mining various sequencing datasets. We also performed meta-analyses to document enrichment of DNMs in candidate genes by leveraging our WGS dataset with those of several DEE/ID series. By combining these strategies, we were able to provide a causal link between DEE and the following genes: NTRK2, GABRB2, CLTC, DHDDS, NUS1, RAB11A, GABBR2 and SNAP25. Overall, we established a molecular diagnosis in 63/197 (32%) individuals of our WGS series. The main cause of DEE in these individuals was de novo point mutations (53/63 solved cases), followed by inherited mutations (6/63 solved cases) and de novo CNVs (4/63 solved cases). De novo missense variants explained a larger proportion of individuals in our series than in other series that were primarily ascertained because of ID. Moreover, these DNMs were more frequently recurrent than those identified in ID series. These observations indicate that the genetic landscape of DEE might be different from that of ID without epilepsy.
INTRODUCTION
Epilepsy is often associated with major comorbidities, most frequently intellectual disability (ID), which affects 25% of children with epilepsy. 1, 2 Conversely, the frequency of life-time history of epilepsy ranges from 7-15% for individuals with mild to moderate ID to 45-82% for those with severe ID. 3 The co-occurrence of epilepsy and ID may involve at least two non-exclusive mechanisms. In some cases, uncontrolled seizures can be detrimental to developing cortical networks, leading to regression and poor cognitive outcomes in children. 4 The term "epileptic encephalopathy" (EE) has been used to designate disorders where the epileptic activity itself contributes to cognitive slowing or regression, and can occur in a child with or without preexisting developmental delay. 5 In other instances, a single genetic or environmental process is sufficient to induce both seizures and cognitive impairment. 6 For instance, mutations that induce specific synaptic defects might result in aberrant connectivity and seizures as well as alter synaptic plasticity and cause learning disabilities. The term "developmental encephalopathy" (DE)" has been proposed to designate disorders where developmental delay emerges prior to the presence of epileptic activity or in the presence of infrequent epileptic activity. 5 Because it is not always easy to dissect the contribution of each of these mechanisms and because some genetic disorders can involve both mechanisms in the same or in different individuals, the term 'developmental and epileptic encephalopathy' (DEE) has been coined to refer to conditions characterized by both ID and epilepsy where both mechanisms may play a role. 5 Recently, parent-child exome sequencing studies in sporadic DEE cases have shown that de novo mutations (DNMs) are an important cause of DEE. However, only a minority of the studied cases were solved by these approaches, thus underlining the genetic heterogeneity of DEE and the need to sequence large cohorts to increase the power to identify novel genes associated with DEE. 7, 8 With an average of ~1 DNM affecting the coding sequence of an individual, one of the challenges has been to determine whether the candidate DNMs are pathogenic or coincidental. To address this, Samocha et al.
(2014) published a statistical framework that determined the rate of de novo variants per gene per class of variant [e.g., missense, nonsense, frameshift, canonical splice site (CSS)] that could be used to determine whether there is gene enrichment for a particular variant class in the studied cohort, thus providing evidence that the observed DNMs are likely implicated in the disease. 9 This strategy was recently successfully employed in meta-analyses of DNMs identified from various ID and/or developmental disorder sequenced trios to identify genes enriched in DNMs in these cohorts. 10, 11 In this study, we performed whole genome sequencing (WGS) on 197 DEE individuals and their unaffected parents. We focused our analyses on DNMs [single nucleotide variations (SNVs), 6 small insertions/deletions (indels)] and copy number variations (CNVs) affecting coding or splice site regions). To identify genes implicated in DEE, we performed meta-analyses combining the DNMs identified in our series along with those found in other studies of DEE or ID trios and looked for genes statistically enriched in DNMs. We also performed targeted sequencing and leveraged our network of collaborators and gene-matching tools to find additional similarly affected cases with DNMs in some of our prioritized genes, thus providing additional support for their implication in the disease. Based on these collective approaches, we provide herein evidence implicating DNMs in 8 genes in DEE.
SUBJECTS AND METHODS
Subjects. The DEE series screened by WGS (n=197 trios) was recruited at three centers in Canada: the Sainte-Justine University Hospital Center in Montreal (HSJ; 99 trios), the Toronto Western Hospital (TWH: 35 trios) and the Hospital for Sick Children in Toronto (HSC; 63 trios), after approval by the ethics research boards and obtaining informed consent from each participant or legal guardian. This series, referred to as the Canadian Epilepsy Network (CENet) DEE cohort, included subjects with diverse DEE phenotypes. The criteria used for the selection of these individuals were as follows: 1)
intractable epilepsy defined as an absence of response to two appropriate and well-tolerated AEDs over a 6-month period and an average of at least one focal, generalized tonic-clonic, myoclonic, epileptic spasms, tonic, atonic or absence seizure per month during the period of poor control; 2) intellectual disability or global developmental delay (GDD); 3) absence of malformations or focal/multifocal structural abnormalities on brain MRI; and 4) absence of parental consanguinity and family history of epilepsy, intellectual disability or autism in first-degree relatives. Each individual was classified into a specific epilepsy syndrome when possible (Table S1 ). The majority (~90% of cases) had had array comparative genome hybridization performed on a clinical basis and only those with no pathogenic or possibly pathogenic CNVs were included. Many of the individuals were previously screened negative for mutations in various DEE gene panel tests. A subset of candidate genes identified in the course of this study were sequenced in a cohort comprised of 595 individuals with EEs of unknown cause (Table   S2 ), most of whom had been tested for mutations in genes previously associated with DEE as well as for pathogenic CNVs, as described. 12 We were also able to recruit, through various collaborations, additional subjects with DNMs in candidate genes identified from clinical or research exomes.
Informed consent was similarly obtained from these individuals or their legal guardians. WGS data processing, variant calling and analyses. The Illumina sequencing reads were generated using bcl2fastq v1.8.4. Trimmomatic v0.32 was used to remove bad quality reads and to trim the read edges with a lower quality. The filtered reads were aligned to reference Homo sapiens assembly b37 (GRCh37) using BWA-mem v0.7.10 to create a Binary Alignment Map file (.bam). Read set BAM files from different sequencing lanes for the same sample were merged into a single global BAM file using Picard v.1.123. Regions containing multiple base mismatches were realigned locally using
Picard. Once local regions were realigned, Picard was also used to recalculate the read mate coordinates and to mark duplicates for removal. Individual base quality values were recalibrated using GATK v.3.3-0. Genotypes were called using GATK Haplotype-Caller and all variant calls were merged and recalibrated in three different sensitivity tranches using GATK and according to its recommended best practices. All variant sites were annotated using a custom version of Annovar.
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Only variants whose positions were covered at ≥10x and supported by at least 4 variant reads constituting ≥ β5% of the total reads for each called position were considered. Rare variants included those present with a minor allele frequency (MAF) of ≤0.005 in 1000 Genomes, GoNL, ExAC vs 0.3, EVS (NHLBI Exome Sequencing Project; ESP) or ≤ 2% in the unaffected parents from the entire trio dataset. A variant segregation analysis (child-parents) was performed using an in-house script. Putative DNMs were identified by excluding those present in the genomes of the parents and those with a MAF ≥ 0.001 in ExAC. Potential de novo variants outside the exonic and splice consensus regions were further excluded if present in small-repeat regions (for SNVs and indels), in Alu regions (for indels) or had a SNV variant quality recalibration score (VQSRT) of ≥ 99.90-to-100.00 or an indel VQSRT different than PASS. The sequencing reads carrying putative DNMs were inspected visually in each trio using the Integrative Genomics Viewer (IGV) 14 to exclude obvious false positives or inherited variants. Putative DNMs affecting the coding and consensus splice regions were validated by Sanger 8 sequencing in the corresponding trio.
CNV analyses. CNVs were identified using two algorithms: Lumpy, whose calls integrate multiple breakpoint signals, and PopSV, whose calls rely on deviation from normalized read-depths across samples. 15, 16 Default parameters were used unless otherwise specified. For PopSV, 5kb bin scans of the genome were used. CNV calls were filtered to exclude those with a size <1kb and qv (PopSV) or evidence set scores (Lumpy) ≤ 0.1%. CNVs falling in regions of segmental duplications were also excluded. To identify de novo CNVs, we excluded those present in any of the parents' samples from the entire data set or in population controls from the 1000 Genomes or from the CNV map high quality datasets of common variants. 17 De novo CNVs called by both Lumpy and PopSV were prioritized for validation. Potential de novo CNVs detected by only 1 algorithm, and thus likely enriched in false positives, were considered for validation only if they affected exonic regions and if they could not be ruled out as inherited or false positives upon visual inspection by IGV of the reads near the breakpoints.
CNVs were validated in the trio using standard qPCR (Taqman assay) and/or by Sanger sequencing.
Targeted sequencing using the Molecular Inversion Probes (MIPs) technique. Seven of our initially prioritized genes (DHDDS, RYR2, HECW2, GABRB2, NUS1, NTRK2 and CLTC) were selected for MIPs sequencing in a cohort of 595 individuals with DEE. We used a multiplex targeted capture strategy to target the coding exons and intron-exon boundaries (a minimum of five base pairs of flanking sequence) in each of the seven genes. Single molecule molecular inversion probes (smMIPs) were used as previously described 18 with minor modifications detailed below. The molecular tag within the probe consisted of five random nucleotides that allowed for distinction of genomic molecules and a high-confidence consensus call. Library preparation remained the same as described by O'Roak et al.
(2012) 19 except the ratio of probe to genomic DNA was adjusted to 2,000:1, a tenfold increase than previously reported. Sequencing was performed on an Illumina HiSeq2500 to generate 100 base pair pair-end reads. Raw read mapping and processing were performed as previously described. 12 Private variants (absent from SNP public databases: ExAC v0.3, EVS, and 1000 Genomes) predicted to affect the protein sequence (missense, nonsense, indels, and canonical splice sites) were validated using Sanger sequencing in the proband and the parents. 8, 21, 22 We also performed another meta-analysis combining DNMs from the DEE cohorts with those from exome or genome sequencing from published ID cohorts. 10, 11, [23] [24] [25] [26] [27] [28] . Only studies consisting of more than 10 trios were included in these meta-analyses (Table S3 ). To further increase the power to detect DNM-gene enrichment in genes whose mutations
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are not yet an established cause of DEE, we applied a similar strategy as Lelieveld et al (2016) 11 who excluded from their meta-analysis trios with DNMs found in their curated list of genes previously associated with ID. Therefore, we performed a meta-analysis after excluding trios with DNMs affecting the autosomal dominant or X-linked genes mentioned in this list (n = 572), which also includes genes associated with DEE, or trios with such mutations in 21 genes not reported in this list but subsequently found enriched with DNMs by Lelieveld et al. (2016) and/or by the recent Deciphering Developmental Disorders (DDD) trio sequencing study.
10,11
Clustering of de novo missense variants. We used the open source program Denovonear used in the DDD Study 10, 29 to calculate the probability of the proximity of de novo missense variants in genes of interest based on 1 million simulations weighted by the context trinucleotide rates. We considered a pvalue < 0.01 as statistically significant.
RESULTS
We performed WGS on 197 individuals with DEE and their unaffected parents. The average coverage of the genomes was 37.9x, with 99% of the genome (GRCh37) bases covered at ≥10x ( Figure   S1 ). The average number of SNVs and indels per genome was ~ 4 182 490 and ~23 532, respectively ( (Table S5) . 8 We did not detect any DNM in the coding or CSS regions of 39 probands (20%) ( Figure   S2A ). Considering only de novo SNVs, 7.8% are predicted to cause a loss of function (nonsense and CSS variants) while 72% to cause a missense change ( Figure S2B ). We compared the de novo SNV rates observed in our DEE individuals with those observed in unaffected siblings of individuals with autism spectrum disorders (ASD; 66.5% missense, 4.8% LoF) 33 or in Icelandic controls (82% missense, 2.7% LoF). 32 We found an excess of LoF SNVs in our EE subjects when compared to these control sibling exomes (p = 0. (Table S6) .
Likely pathogenic variants identified in the CENet series
For all DNMs and rare recessive variants (bi-allelic, X-linked hemizygous) affecting the coding regions or CSS, we assessed the involvement of the corresponding genes in epilepsy or related neurodevelopmental disorders by searching Pubmed [Gene name and ("epileptic encephalopathy" or "epilepsy" or "seizure" or "mental retardation" or "intellectual disability")] and verifying the gene's OMIM description. Using the ACMG 2015 guidelines for sequence variant interpretation, 34 we initially identified pathogenic or likely pathogenic variants in 50/197 subjects (25%) in genes which, when mutated, have been shown to cause DEE and/or ID. Of these, 88% were explained by DNMs and 12%
were caused by inherited recessive mutations (Tables 1, S5 and S7).
We also identified pathogenic de novo CNVs in 3 individuals, including a 8 Mb deletion encompassing PCDH19 (OMIM 300460) in a female individual, a 5.2 Mb duplication corresponding to the 15q11-q13 region located between the recurrent breakpoints BP2-BP3 and a 3.4 kb exonic deletion of DNMT3A (OMIM 615879), all of which have been previously associated with ID and/or epilepsy.
Targeted MIPs sequencing
From the WGS results of our first 120 DEE trios, we prioritized 7 of our best candidate genes (CLTC, DHDDS, GABRB2, HECW2, NTRK2, RYR2 and NUS1) for targeted resequencing in 595 unsolved DEE cases. These genes were selected based on the documentation of predicted-damaging DNMs in at least 2 unsolved individuals from the CENet series or in 1 unsolved individual from the CENet series and in at least 1 previously reported case with DEE and/or ID. Exon-1 of NUS1 was excluded from the analysis because it was poorly covered across the samples (18% of the target bases at ≥10x), possibly due to its high GC content. On average, 90% of the target bases were covered at (p.Tyr244His) and NTRK2 (p.Tyr434Cys) were also recurrent in the CENet series. The missense (p.Arg1495Lys) in HECW2 is also recurrent as it was previously reported as a de novo variant in a DDD case. 10 Recently DNMs in HECW2 have been shown to cause DEE.
25,35

Involvement of NTRK2, GABRB2, CLTC, DHDDS and NUS1 in DEE
We next sought to identify additional individuals with DEE or ID who carry DNMs in the candidate genes that were prioritized for MIPs sequencing by mining GeneMatcher 36 and DDD/Decipher 37 and by contacting our network of collaborators. Through this approach, we were able to obtain additional supporting evidence for the involvement of the following genes in DEE. presented with a similar phenotype as that of our subject, including excessive weight gain, moderate ID, language delay, autistic features, hypotonia and seizures.
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NTRK2 encodes the TrkB receptor, a member of the neurotrophin receptor tyrosine kinase family. 39 TrkB has high affinity for the brain derived neurotrophic factor (BDNF) and for neurotrophin-4 (NT4). BDNF-TrkB signalling is a critical regulator of neuronal development and function. 40 The p.Tyr434Cys variant is located at the beginning of the transmembrane domain (TM) of NTRK2 ( Figure   1A ). The fact that this de novo variant has been identified in 4 cases with a similar phenotype suggests that it confers a specific property to the protein, possibly via a gain-of-function or a dominant-negative mechanism. The p.Thr720Ile and p.Tyr722Cys variants cluster in the catalytic domain of NTRK2
( Figure 1A) . In vitro studies indicate that p.Tyr722Cys impairs BDNF-induced TRKB receptor autophosphorylation and downstream signalling. 38 It is currently unknown whether the p.Thr720Ile affects NTRKβ's function in a similar way but its proximity to p.Tyr722Cys and the similarity in the phenotype of both individuals carrying these mutations suggest that this could be the case.
Interestingly, mice expressing 25% of TRKB levels are hyperphagic and have excessive weight. 41 Altogether, our findings unequivocally show that DNMs in NTRK2 cause DEE. Figure 1B .
GABRB2. Our WGS and MIPs screens identified 3 individuals with DEE carrying DNMs in
We were able to obtain detailed clinical information for all of these 11 individuals ( GABRB2 encodes the β subunit of the GABAA receptor, a neuronal pentameric ionotropic ligand-gated chloride channel that induces synaptic inhibition when activated by its agonist GABA. 43 Mutations in other GABAA receptor subunits encoding GABRA1 (OMIM 137160), GABRB1 (OMIM 137190), GABRB3 (OMIM 137192) and GABRG2 (OMIM 137164) are established causes of DEE.
Three cases with DNMs in GABRB2 and detailed phenotypic information have been previously published: one of these subjects, who carries the DNM p.Met79Thr, also found in one of our cases, showed generalized seizures and moderate ID, another one displayed ID, seizures (of unspecified type) and cortical visual impairment (c.754C>G: p.Pro252Ala) and the last one was found to have earlyonset myoclonic encephalopathy (c.859A>C: p.Thr287Pro) . 44 45,46 Four additional cases with de novo
(p.Lys303Asn), c.911C>T (p.Ala304Val), have been reported. [47] [48] [49] The amino acid residues affected by the latter two of these DNMs (p.Lys303Asn and p.Ala304Val) were also found mutated in our series.
These 4 individuals appear to show ID/GDD and epilepsy but no detailed clinical information was available.
Out of the 13 DNMs in GABRB2 previously reported or described herein, 10 are clustered within a stretch of 60 amino acids (positions 244-304) encompassing 3 transmembrane domains and/or their boundaries (p-value = 0.000002, Denovonear) ( Figure 1B identified by the DDD study 10 , while the other 7 we identified through clinical WES (Table 4; Supplemental Note). We were able to obtain detailed clinical information for all of these 12 Figure 1C .
CLTC encodes the widely expressed clathrin heavy chain 1, which is involved in endocytosis, intracellular trafficking and synaptic recycling. 50, 51 Recently, a de novo frameshift in CLTC (c.2737_2738dupGA p.Asp913Glufs*59) was reported in a subject with GDD, unclassified epilepsy and dysmorphic features. 52, 53 Two additional DNMs were also reported by Leliveld et al. (2016) 11 from their study of 800 probands with ID, including c.4615C>T (p.Glu1539*) and c.3621_3623del
(p.Asp1207del), the latter being also identified in one of our DEE cases. CLTC is predicted intolerant to LoF mutations with a pLi score of 1.00 according to ExAC. 54 The phenotypic spectrum associated with these cases is heterogeneous ranging from mild ID or learning disability to severe ID or DEE.
Interestingly, individuals with refractory epilepsy were found to carry mutations in the first section of the clathrin LC binding domain, whereas de novo truncating mutations at the C-terminus of CLTC tended to be associated with hypotonia, GDD and ID ( Figure 1C ). information on a third subject, also with the same de novo p.Arg211Gln (indvNCJ herein), who was previously reported in a recent WES study of ID trios. 11 The positions of these various identified DNMs in DHDDS are shown in Figure 1D and their associated phenotype are summarized in Table 5 and detailed in the Supplemental Note. DHDDS encodes dehydrodolichyl diphosphate synthase (also known as hCIT), which is essential for dolichol monophosphate (Dol-P) synthesis and global N-linked glycosylation. 55 The
DHDDS. WGS identified a de novo
Arg37 and Arg38 residues fall into an evolutionary conserved stretch of 5 amino-acids (pos. [34] [35] [36] [37] [38] corresponding to the catalytic domain of the enzyme ( Figure 1D ). Based on the crystal structure and mutagenesis studies done on the bacterial Dhdds enzyme (M. luteus ndecaprenyl diphosphate synthase, UDPS), the Arg203 residue, which is equivalent to Arg211 in the human DHDDS, is critical for the homoallylic binding to the substrate isopentenyl diphosphate. 56, 57 The identification of recurrent or clustering DNMs in individuals with a similar phenotype in DHDDS is highly suggestive of pathogenicity.
A homozygous missense variant (c.124A>G: p.Lys42Glu) was previously found in DHDDS in consanguineous families with retinitis pigmentosa. 58, 59 In addition, bi-allelic truncating/splicing variants in DHDDS were reported in a case of type I congenital disorder of glycosylation with severe GDD and refractory seizures. 60 We hypothesize that null alleles of DHDDS disrupt brain development only in in the context of a recessive genotype whereas the DNMs documented in our study cause DEE via a dominant-negative or gain-of-function mechanism. (Table 5 , Supplemental Note; Figure 1E ). These cases with DNMs in NUS1 all presented with GDD (or isolated motor delay), evolving towards mild to severe ID. Furthermore, they all presented generalized myoclonic seizures (in one case with myoclonic status epilepticus), combined with myoclonic absences in 2 cases. In all cases, other generalized seizure types were observed, including atonic seizures (drop attacks) or generalized tonic-clonic seizures. EEGs revealed either generalized epileptic activity or bifrontal epileptic discharges. Movement disorders were also common, including tremor (2 cases) and ataxia (one case). Together, this clinical phenotype is highly reminiscent of the one we observed in cases with DNMs in DHDDS.
NUS1. We identified 2 DNMs in
NUS1 encodes the Nogo-B receptor (NgBR) which physically interacts with DHDDS to stabilize the dehydrodolichyl diphosphate synthase complex and potentiate its enzymatic activity. 55, 61 Both indel mutations identified in this study affect upstream exons, thus having the potential of inducing nonsense mediated decay of the transcript. In addition, both variants are predicted to abolish the conserved C-terminal domain, which is required for the interaction with DHDDS. 61 The deletion of exon-2 causes an in-frame deletion of amino acids 139-180 leading to the loss of TM3 which is critical for the proper topology of NUS1. Previously, a homozygous missense mutation affecting its Cterminus (c.869G>A: p.Arg290His) was identified in 2 siblings with type 1a congenital disorder of glycosylation and a severe phenotype of early onset refractory epilepsy, congenital scoliosis, developmental delay with hypotonia, microcephaly, hearing and visual impairment as well as severe cortical atrophy. 62 This mutation was found to decrease cis-PTase activity when expressed with hCIT (DHDDS) in yeast. In addition, Szafrans et al. (2015) reported cases with early onset seizures and microdeletions of chromosome 6q22.1, which are centered on a 250 kb critical region that only includes NUS1 and the promoter of SLC35F1. 63 Collectively, our finding of DEE cases with 2 truncating DNMs and 1 de novo whole exon deletion in NUS1, the reported DEE cases with NUS1 microdeletions and the fact that NUS1 is a functional direct interactor of DHDDS suggest that heterozygous mutations in NUS1 can cause DEE, possibly via a mechanism of haploinsufficiency. This is in agreement with the fact that NUS1 does not tolerate LoF variants as suggested by the ExAC dataset where no such LoF mutations were reported (pLi = 0.87). 54 The more severe phenotype previously observed in the siblings with the homozygous p.Arg290His mutation could be due to a more dramatic reduction in NUS1 activity due to the recessive nature of a potentially hypomorphic mutation. Failure to identify other cases with NUS1 truncating mutations from the MIPs screen or other EE published trios maybe in part due to reduced capture efficiency of exon-1, which encodes 137/293 amino acids of NUS1 (~ 47%). Indeed, in the ExAC database, exon-1 of NUS1 is, on average, poorly covered by WES compared to the rest of exons of this gene.
Meta-analyses of DNMs from DEE and DEE-ID cohorts
In order to further assess the involvement of various candidate genes in DEE, we sought to determine whether DNMs were enriched in certain genes in series of affected individuals by taking advantage of a statistical framework that is based on the use of gene-specific mutation rates. 9 To increase power, we meta-analyzed DNMs from our DEE cohort along with DNMs from published WES DEE trio studies (combined DEE trios = 624; Table S3 ). In total, 12 genes were found to be statistically enriched for LoF and/or functional DNMs (Table 6 ); mutations in all of these genes are now considered causative of DEE.
As epilepsy is a frequent co-morbidity of ID, we performed a second meta-analysis combining the DNMs from published ID trios with those from the DEE-cohorts used above (DEE-ID cohorts:
5948 trios: 7778 DNMs). In total, 111 genes were found enriched for functional and/or LoF DNMs, 37 of which were found mutated in at least one DEE case (Table S8) (Table S8 ).
Lelieveld et al. (2016) recently showed increased power to detect novel ID-associated genes in a meta-analysis after excluding individuals with DNMs in genes previously found to be causally linked to ID. 11 We applied here a similar strategy to both the DEE-ID cohort and excluded individuals with DNMs in any of the genes mentioned in the list established by these authors. 11 We also removed the cases with DNMs in genes that showed DNM enrichment from the recent meta-analyses done on ID/developmental disorder trios. 10, 11 This retained 4424 trios from the combined DEE-ID cohorts. . As shown below, we also provide additional evidence for the involvement of RAB11A, and GABBR2 and SNAP25 in DEE.
RAB11A (NM_004663.3). We found a de novo predicted-damaging missense variant in
RAB11A (c.244C>T: p.Arg82Cys) in a CENet case with refractory epileptic spasms and erratic myoclonus with developmental regression. She subsequently developed focal seizures and severe ID.
We also identified by WES another predicted-damaging de novo missense in RAB11A (c.71A>G: p.Lys24Arg) in an individual with moderate GDD and an abnormal EEG but with no seizures reported so far. Three additional individuals with DNMs in RAB11A were identified in the context of the DDD study 10 , including 2 individuals with the same variant (c.461C>T: p.Ser154Leu) and another individual with a different variant (c.39A>C: p.Lys13Asn). We were able to obtain detailed clinical information on the cases with the p.Ser154Leu variant that both showed moderate GDD without epilepsy. The other individual from the DDD study had abnormalities of the nervous system according to the Decipher database but we could not get additional clinical information. Brain atrophy and/or abnormalities of the corpus callosum were noted for three of the individuals with available MRI information ( Table 7; Supplemental Note).
RAB11A encodes a GTPase that regulates the recycling of a wide range of receptors at the cell surface. 65 Interestingly, RAB11A regulates synaptic plasticity by modulating the endocytic recycling of NTRK2 and AMPA receptors at the post-synaptic membrane of neurons. [66] [67] [68] The highly conserved Arg82 residue is located in the nucleotide-sensitive switch domain II of RAB11A and is involved in binding to the RAB11A effector FIP3. 69, 70 The p.Lys24Arg, p.Lys13Asn and p.Ser154Leu mutations do not affect any of the nucleotide-sensitive switch domains of RAB11A ( Figure 1F ). The fact that RAB11A is enriched in DNMs in the DEE-ID cohorts and found with a recurrent de novo missense in 2 cases of the DDD cohort, suggests that DNMs in this gene can cause a DEE or ID phenotype.
GABBR2.
We identified from our WGS a de novo missense in GABBR2 (NM_005458. 
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GABBR2 encodes a -aminobutyric acid type B receptor that inhibits neuronal activity through G protein-coupled second-messenger signaling, present both at the presynaptic and post-synaptic membrane where it regulates neurotransmitter release and the activity of ion channels. 71 The receptor is the target of baclofen, a medication often used to treat spasticity. The hypotonia and hyporeflexia Collectively, these findings support the involvement of SNAP25 mutations in DEE.
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Pattern of DNMs associated with DEE
Out of the 53 pathogenic or likely pathogenic de novo point variants identified in our CENet series, 35 are missense and 15 are LoF, resulting in a missense/LoF ratio of 2.5 (Table S5) LoF) were also reported independently in ClinVar] (p = 0.0012, 2-tailed Fischer's exact test) 23, 24, 26, 28 .
DISCUSSION
In this study, we performed WGS on 197 individuals with DEE and their unaffected parents.
We initially identified pathogenic variants in 53/197 cases (27%), including 50 cases with point mutations in genes previously found to be causally linked to DEE/ID, 1 with a recurrent pathogenic CNV (15q11-q13 duplication) and 2 cases with CNVs encompassing genes previously associated with ID or DEE (PCDH19 and DNMT3A). Moreover, we were able to explain DEE in 10 additional individuals from the series by identifying DNMs in candidate genes for which we provide additional evidence for their involvement in DEE (NTRK2, GABRB2, CLTC, DHDDS, NUS1, RAB11A, GABBR2
and SNAP25). Overall, our approach allowed us to obtain a molecular diagnosis in 63/197 (32%) individuals. It is important to note that the diagnostic yield of WGS would have likely been higher in an unbiased series since many of our subjects had previously been screened by clinical targeted sequencing and/or array genomic hybridization. Interestingly, 2 of the 4 pathogenic de novo CNVs identified in our series would have been missed by clinical array genomic hybridization because of their size (˂ 5 kb), providing some support for the added value of WGS.
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The main cause of DEE in our series was de novo point mutations (53/63 solved cases), the remaining cases being explained by inherited mutations (6/63 solved cases) or de novo CNVs (4/63 solved cases). De novo missense variants explained a larger proportion of individuals with DEE in our series than individuals from other series that were primarily ascertained because of ID. Interestingly, more than half of these pathogenic missense mutations were recurrent, suggesting that at least a subset of them confer a specific property to the protein such as dominant-negative or gain-of-function effects.
Shohat et al. (2017) recently showed that genes with LoF mutations compared to genes with missense mutations were associated with different pathways across neuro-developmental disorders such as ID, autism spectrum disorder and schizophrenia. 79 For instance, genes with missense variants involved in neuro-developmental disorders code for proteins that show a higher number of protein interactions when compared to genes with LoFs. Altogether, this data raises the possibility that the genetic landscape of DEE is enriched for gene products that act as protein hubs. It would be important to understand why these hubs are specifically associated with DEE.
Of the 8 genes highlighted herein for their involvement in DEE, we were not able to show de novo gene-enrichment for 3 of them, NTRK2, DHDDS and NUS1. However, the multiple occurrences of DNMs affecting the same conserved amino acid residues in NTRK2 and DHDDS in cases with a similar phenotype, nonetheless, represents a strong evidence implicating these genes in DEE. Indeed, other DEE-related genes with site-specific recurrent DNMs, such as GRIN2D (OMIM 300776) and FGF12 (OMIM 601513), did not also show DNM enrichment in our meta-analyses. Genetic forms of neuro-developmental disorders that are caused by recurrent DNMs associated with gain-of-function or dominant negative effects tend to be rare because there are typically a smaller number of variants that can confer such effects than variants that can induce haploinsufficiency. It is thus likely that metaanalyses involving larger number of subjects will be necessary to identify these rare forms of DEE. No DNM enrichment was observed for NUS1 in our meta-analysis, possibly due to the poor capture of its exon-1, which represents almost half of the entire coding sequence of this gene. However, the identification of 3 DNMs in NUS1 (including 2 truncating variants and a microdeletion) in DEE cases with similar phenotypes and the fact that NUS1 is a functional direct interactor of DHDDS strongly support the involvement of this gene in DEE.
Several of the DEE-related genes highlighted in this study code for proteins that interact directly or indirectly with other proteins encoded by genes associated with epilepsy. This is the case for: 1) DHDDS and NUS1, which form a complex for the synthesis of dolichol monophosphate 55,61 ; 2) SNAP25, which interacts with the DEE-associated STXBP1 for the docking of neurotransmitter 23 vesicles; and 3) RAB11A, which is involved in the endocytosis of NTRK2. 68 In addition, GABRB2
and GABBR2 both belong to the family of GABAergic receptors, which include other members 
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